Small logo Subscribe to leading news on impact investing. Learn More
The Brief Originals Dealflow Signals The Impact Alpha Impact Voices Podcasts Agents of Impact Open
What's Next Capital on the Frontier Measure Better Investing in Racial Equity Beyond Trade-offs Impact en las Americas New Revivalists
Local and Inclusive Climate Finance Catalytic Capital Frontier Finance Best Practices Geographies
Slack Agent of Impact Calls Events Contribute
The Archive ImpactSpace The Accelerator Selection Tool Network Map
About Us FAQ Calendar Pricing and Payment Policy Privacy Policy Terms of Service Agreement Contact Us
Locavesting Entrepreneurship Gender Smart Return on Inclusion Good Jobs Creative economy Opportunity Zones Investing in place Housing New Schooled Well Being People on the Move Faith and investing Inclusive Fintech
Clean Energy Farmer Finance Soil Wealth Conservation Finance Financing Fish
Innovative Finance
Personal Finance Impact Management
Africa Asia Europe Latin America Middle East Oceania/Australia China Canada India United Kingdom United States
Subscribe Log In

Demo Day for a COVID-focused accelerator opens to the public

ImpactAlpha, July 27 – Demo days have become Silicon Valley legend, or cliche, by now: anxious startup founders pitch business plans honed over the course of an accelerator program to an elite audience of angel and venture investors.

XX, an accelerator spun out of the crowdfunding site WeFunder, is changing things up.

On July 28 at 9 am EST, a dozen startups from its third cohort will pitch COVID-related solutions, from potential vaccines to virtual reality software, at an online demo day. The twist: anyone can invest – with as little as $100.

“We’re giving a chance to anyone that cares about this mission, or where the next vaccine is coming from,” says Gadi Borovich, a partner with XX.

The startups were selected from among 2,500 that applied to XX’s Fight the Virus challenge, and each received $50,000 from an XX fund.

On the agenda: Stark Therapeutics is working on a COVID-19 vaccine using a protein from the SARS virus to train the body’s T cells to target infected cells. Precision therapeutics company Petri Bio is developing peptides that could neutralize the virus. VivaVax makes an antiviral coating that eliminates microbes and 3C Bio is producing mobile testing labs.

Other cohort teams are pursuing indirect solutions to the COVID crisis, such as virtual reality software for teams or robotic delivery.

Previous XX cohorts have focused on women and immigrant founders.

The demo day will be hosted on WeFunder. Each startup has a lead investor from XX’s network, who has vetted and invested in the company on the same terms being offered on demo day.

Grassroots platforms are not waiting for Washington to invest in a green new deal

Unaccredited investors collectively can invest up to $1.07 million in each of the 14 companies under a crowdfunding securities exemption. High net worth, angel and venture investors can invest unlimited sums through a parallel “Regulation D” offering.

You might also like...